These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

116 related articles for article (PubMed ID: 3045271)

  • 1. Value of myocardial defect size measured by thallium-201 SPECT: results of a multicenter trial comparing heparin and a new fibrinolytic agent.
    Maublant JC; Peycelon P; Cardot JC; Verdenet J; Fagret D; Comet M
    J Nucl Med; 1988 Sep; 29(9):1486-91. PubMed ID: 3045271
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Anisoylated plasminogen streptokinase complex during the acute phase of myocardial infarction. Results of a multicenter double-blind study versus heparin].
    Cassagnes J; Bassand JP; Machecourt J; Lusson JR; Anguenot T; Borel E; Vacher D; Denis B; Maurat JP; Jallut H
    Arch Mal Coeur Vaiss; 1990 Apr; 83(4):453-60. PubMed ID: 2111665
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Multicenter trial of intravenous anisoylated plasminogen streptokinase activator complex (APSAC) in acute myocardial infarction: effects on infarct size and left ventricular function.
    Bassand JP; Machecourt J; Cassagnes J; Anguenot T; Lusson R; Borel E; Peycelon P; Wolf E; Ducellier D
    J Am Coll Cardiol; 1989 Apr; 13(5):988-97. PubMed ID: 2647817
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Assessment of left ventricular function in a randomised study of intravenous anisoylated plasminogen streptokinase activator complex versus heparin in acute myocardial infarction. Preliminary results of the European Multicentre Study (Belgian Centres).
    Taeymans Y; Materne P
    Drugs; 1987; 33 Suppl 3():216-20. PubMed ID: 3315594
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effects on infarct size and left ventricular function of early intravenous injection of anistreplase in acute myocardial infarction. The APSIM Study Investigators.
    Bassand JP; Bernard Y; Lusson JR; Machecourt J; Cassagnes J; Borel E
    Clin Cardiol; 1990 Mar; Suppl 5():V39-44; discussion V67-72. PubMed ID: 2182240
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparison in acute myocardial infarction of anisoylated plasminogen streptokinase activator complex versus heparin evaluated by simultaneous thallium-201/technetium-99m pyrophosphate tomography.
    Krause T; Kasper W; Meinertz T; Schnitzler M; Just H; Schümichen C; Moser E
    Am J Cardiol; 1993 Jan; 71(1):8-13. PubMed ID: 8420241
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The German multicenter trial of anisoylated plasminogen streptokinase activator complex versus heparin for acute myocardial infarction.
    Meinertz T; Kasper W; Schumacher M; Just H
    Am J Cardiol; 1988 Sep; 62(7):347-51. PubMed ID: 3046283
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Multicenter reperfusion trial of intravenous anisoylated plasminogen streptokinase activator complex (APSAC) in acute myocardial infarction: controlled comparison with intracoronary streptokinase.
    Anderson JL; Rothbard RL; Hackworthy RA; Sorensen SG; Fitzpatrick PG; Dahl CF; Hagan AD; Browne KF; Symkoviak GP; Menlove RL
    J Am Coll Cardiol; 1988 Jun; 11(6):1153-63. PubMed ID: 3284943
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The effect of thrombolytic therapy with anisoylated plasminogen streptokinase activator complex on the indicators of myocardial salvage.
    Buchalter MB; Bourke JP; Jennings K; Adams PC; Kenmure AC; Hah CW; Reid DS
    Drugs; 1987; 33 Suppl 3():209-15. PubMed ID: 3315593
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Analysis of coagulation and fibrinolysis after intravenous anisoylated plasminogen streptokinase activator complex or heparin in patients with acute myocardial infarction. A Belgian multicentre study.
    Renkin J; Beys CC; Lavenne-Pardonge E; Pintens H; Col J
    Drugs; 1987; 33 Suppl 3():253-60. PubMed ID: 3315603
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Limitation of myocardial infarct size and preservation of left ventricular function by early administration of APSAC in myocardial infarction.
    Bassand JP; Machecourt J; Cassagnes J; Lusson JR; Borel E; Schiele F
    Am J Cardiol; 1989 Jul; 64(2):18A-23A; discussion 24A-26A. PubMed ID: 2662738
    [TBL] [Abstract][Full Text] [Related]  

  • 12. An interim report of a double-blind placebo-controlled recanalisation study of anisoylated plasminogen streptokinase activator complex in acute myocardial infarction.
    Timmis AD; Griffin B; Crick JC; Flax JS; Sowton E
    Drugs; 1987; 33 Suppl 3():146-50. PubMed ID: 3315582
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effect of reperfusion on electrocardiographic and enzymatic infarct size: results of a randomized multicenter study of intravenous anisoylated plasminogen streptokinase activator complex (APSAC) versus intracoronary streptokinase in acute myocardial infarction.
    Hackworthy RA; Sorensen SG; Fitzpatrick PG; Barry WH; Menlove RL; Rothbard RL; Anderson JL
    Am Heart J; 1988 Oct; 116(4):903-14. PubMed ID: 3051985
    [TBL] [Abstract][Full Text] [Related]  

  • 14. AIMS. The design and conduct of a multicentre mortality study comparing placebo and anisoylated plasminogen streptokinase activator complex 30 units intravenously for the treatment of acute myocardial infarction of less than 6 hours duration. UK APSAC Advisory Committee.
    Drugs; 1987; 33 Suppl 3():227-8. PubMed ID: 3315598
    [No Abstract]   [Full Text] [Related]  

  • 15. Comparison of intravenous anisoylated plasminogen streptokinase activator complex and intracoronary streptokinase in acute myocardial infarction.
    Bonnier HJ; Visser RF; Klomps HC; Hoffmann HJ
    Am J Cardiol; 1988 Jul; 62(1):25-30. PubMed ID: 3289357
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Electrocardiographic and enzymatic infarct size in a randomised study of intracoronary streptokinase and intravenous anisoylated plasminogen streptokinase activator complex in acute myocardial infarction.
    Hackworthy RA; Sorensen SG; Menlove RL; Anderson JL
    Drugs; 1987; 33 Suppl 3():198-208. PubMed ID: 3315592
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparative effects of APSAC and rt-PA on infarct size and left ventricular function in acute myocardial infarction. A multicenter randomized study.
    Bassand JP; Cassagnes J; Machecourt J; Lusson JR; Anguenot T; Wolf JE; Maublant J; Bertrand B; Schiele F
    Circulation; 1991 Sep; 84(3):1107-17. PubMed ID: 1909218
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Preliminary safety and tolerance data obtained in the comparative study of anisoylated plasminogen streptokinase activator complex versus heparin.
    Croydon EA
    Drugs; 1987; 33 Suppl 3():293-6. PubMed ID: 3315611
    [TBL] [Abstract][Full Text] [Related]  

  • 19. ISIS-3: a randomised comparison of streptokinase vs tissue plasminogen activator vs anistreplase and of aspirin plus heparin vs aspirin alone among 41,299 cases of suspected acute myocardial infarction. ISIS-3 (Third International Study of Infarct Survival) Collaborative Group.
    Lancet; 1992 Mar; 339(8796):753-70. PubMed ID: 1347801
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Safety and tolerance data from the Belgian multicentre study of anisoylated plasminogen streptokinase activator complex versus heparin in acute myocardial infarction.
    Bossaert LL
    Drugs; 1987; 33 Suppl 3():287-92. PubMed ID: 3315610
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.